NASDAQ: AMRX · Specialty & Generic Drug Manufacturers
Amneal Pharmaceuticals (AMRX) fair value and price range
As of 14 Nov 2026, Faircurve's model values Amneal Pharmaceuticals (AMRX) at $19.34 a share. The stock last closed at $21.12, which puts the model's fair value 8.4% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 17 Nov 2026. Amneal Pharmaceuticals, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $21.14 to $19.34 (-8.5%). The model changed its method this week; the move is not broken down.
What the model makes of itThe price of $21.12 is 8.4% above it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 26 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give AMRX?
The calibrated range for AMRX over 63 trading days is $18.70 to $23.99. It sits around the last close, and its width comes from the volatility that AMRX's own options imply (37% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $13.96 to $25.85. In 39% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Amneal Pharmaceuticals, Inc. is a diversified pharmaceutical company. It is involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialised medicinal.
Faircurve's model puts the fair value of Amneal Pharmaceuticals at $19.34 a share, as of 14 Nov 2026. It is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $21.14, so the fair value moved -8.5%. The model changed its method this week, and the move is not broken down. The calibrated range over 63 trading days is $18.80 to $24.12, built around the price from the stock's own options-implied volatility. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade covers input completeness, comparable companies and range width. It does not say whether the fair value is right.
Amneal scores 54 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Profitability scores 69, with ROIC at 12.5% against a peer median of 7.0%. Stability scores 86, with five-year EBITDA margin downside volatility at 1.5 points against a peer median of 10.5 points. Balance sheet scores 10, with net debt to EBITDA at 4.68x. The model compares the company with Alkermes plc, Viatris Inc., Zoetis Inc. and ANI Pharmaceuticals, Inc.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does AMRX report earnings, and how has the stock reacted?
Amneal Pharmaceuticals's next earnings report is scheduled for 26 Feb 2027. Companies can move their dates.
On 17 Nov 2026, AMRX's 30 day implied volatility worked out to a move of about 10.6% over one month, in either direction. That is a size, not a direction.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across AMRX's last 8 reports, ignoring direction, was 3.4%.
What the options market has priced for a month's move in AMRX
How does AMRX score on business quality?
Amneal Pharmaceuticals's overall quality score is 54 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 69 | 12.5%ROIC | 7.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 37 | 0.27xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 53 | 8.0%Revenue growth, trailing | 4.3% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 55 | 0.0%Net buybacks / market value | 0.2% |
| Balance sheetNet debt to EBITDA and interest coverage. | 10 | 4.68xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 86 | 1.5 ptsEBITDA margin downside volatility, 5y | 10.5 pts |
How does AMRX compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Amneal Pharmaceuticals in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ALKS Alkermes plc | $45.45 | $46.51 | +2.3% | Fairly valued |
| LNTH Lantheus Holdings, Inc. | $101.80 | $100.47 | -1.3% | Data under review |
| ELAN Elanco Animal Health Incorporated | $25.85 | $25.34 | -2.0% | Low evidence grade |
| VTRS Viatris Inc. | $20.45 | $26.77 | +30.9% | Undervalued |
| SUPN Supernus, Inc. | $29.04 | $29.86 | +2.8% | Low evidence grade |
| ZTS Zoetis Inc. | $83.48 | $83.75 | +0.3% | Fairly valued |
| ANIP ANI Pharmaceuticals, Inc. | $69.99 | $78.16 | +11.7% | Fairly valued |
| PAHC Phibro Animal Health Corporation | $34.92 | $36.25 | +3.8% | Low evidence grade |
What the comparable companies' multiples alone would give for AMRX, the peer-implied price, is $7.48 a share on this run. The fair value weighs that against the company's own multiple.
All specialty & generic drug manufacturer stocks ranked by gap to fair value
Amneal Pharmaceuticals at a glance
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal.
- Market value
- $7.4B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $3.5B
- Consensus revenue growth, next fiscal year
- +6.4%
- Analysts with estimates
- 4
- Beta to the US market
- 0.56
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Amneal Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for AMRX was $21.14. As of 14 Nov 2026 it is $19.34, a change of -8.5%. The model changed its method this week; the move is not broken down. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Amneal Pharmaceuticals's valuation
Is Amneal Pharmaceuticals stock undervalued or overvalued?
Faircurve's model puts AMRX's fair value at $19.34 a share against a last close of $21.12, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is AMRX's fair value?
$19.34 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $13.96 to $25.85.
What price range does the model give AMRX?
$18.70 to $23.99 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Amneal Pharmaceuticals report earnings next?
The next report is scheduled for 26 Feb 2027. Companies can move their dates.
How much has AMRX moved on past earnings reports?
Across its last 8 reports the median two session move was 3.4%, ignoring direction. The largest was -5.0% around the report of 27 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for AMRX is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on AMRX
The model holds no idea open on AMRX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on AMRX with their outcomes. A free account is enough.